MedPath

Zonisamide for prevention of Atypical (Second generation) antipsychotics associated weight gain in schizophrenia

Phase 2
Completed
Conditions
schizophrenia.
Schizophrenia
Registration Number
IRCT201103283930N5
Lead Sponsor
Vice chancellor for research, Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
56
Inclusion Criteria

Inclusion criteria are: age range of 16 to 65; lack of any reported neurological disease; lack of reported thyroid function problem; lack of current active substance use; lack of taking medication leading to significant weight gain or loss; no taking sulfanomides; lack of self reported kidney stone. Exclusion criteria are: lack of providing written consent; any serious medical condition such as epilepsy, thyroid function problems, diabetes; breast feeding; pregnancy; any special nutritional regime or intensive exercise program to decease weight.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.